At least two EU countries plan to resume using AstraZeneca’s coronavirus vaccine if regulators give a green light this week.
Officials said France and Italy agreed to resume their rollout of the British drugmaker’s shot “immediately” if the European Medicine Agency formally confirms that people who develop blood clots It is safe to use amid concerns.
After review of blood clotting cases, drug regulator Stand out from its estimation The benefits of the AstraZeneca vaccine relieve its risks. An EMA committee has been informed to issue formal findings and possible recommendations about the concerns at Thursday’s meeting.
Italian Prime Minister Mario Draghi’s office called the EMA’s statement “encouraging” after discussing the AstraZeneca vaccine by phone with French Prime Minister Emmanuel Macron on Tuesday.
“In the event of a positive conclusion to the EMA analysis, both leaders are ready to resume administration of the AstraZeneca vaccine immediately.” Puli’s office said in a statement.
Italy and France are among more than a dozen countries that have halted the use of AstraZeneca vaccines, among which a few have died, amid concerns that a handful of vaccinated people may develop blood clots.
But the EMA, AstraZeneca and the World Health Organization have indicated that there is no evidence that the vaccine caused blood clots.
EMA Executive Director Emer Cook stated, “While the investigation is ongoing, we are strongly convinced that the benefits of the AstraZeneca vaccine to prevent COVID-19, along with the risk of hospitalization and death, are these side effects.” Told about the risk of. ” A tuesday Talk.
EMA officials said the agency is evaluating data on blood clotting cases that have occurred among vaccinated Europeans, which is no more than in the general population.
The results of that assessment will be discussed in Thursday’s meeting and made public thereafter, Cook said.
“Trust in the safety and efficacy of vaccines that we authorize is paramount for us,” she said. “And our job is to ensure that we can maintain confidence in these vaccines based on proper scientific evaluation.”
US-listed shares of AstraZeneca were down 0.7 percent at $ 49.70 in premarket trading as of 8:05 a.m. Wednesday.
With post wires
Leave a Reply